Protagenic Therapeutics Faces Delisting Concerns
Ticker: PTIXW · Form: 8-K · Filed: Nov 22, 2024 · CIK: 1022899
| Field | Detail |
|---|---|
| Company | Protagenic Therapeutics, Inc.\New (PTIXW) |
| Form Type | 8-K |
| Filed Date | Nov 22, 2024 |
| Risk Level | high |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $2,500,000 |
| Sentiment | bearish |
Sentiment: bearish
Topics: delisting, listing-standards, sec-filing
Related Tickers: PTIX
TL;DR
PTIX might be getting delisted from Nasdaq - big trouble ahead.
AI Summary
Protagenic Therapeutics, Inc. filed an 8-K on November 22, 2024, reporting a notice of delisting or failure to satisfy a continued listing rule or standard. The company's common stock was previously listed on the Nasdaq Capital Market under the ticker symbol PTIX. The filing indicates a potential transfer of listing, but specific details regarding the new listing or the reasons for delisting are not provided in this excerpt.
Why It Matters
This filing signals potential issues with Protagenic Therapeutics' continued listing on a major exchange, which could impact its stock liquidity and investor confidence.
Risk Assessment
Risk Level: high — A notice of delisting or failure to meet listing standards indicates significant financial or operational distress for the company.
Key Players & Entities
- Protagenic Therapeutics, Inc. (company) — Filer of the 8-K report
- PTIX (company) — Ticker symbol for Protagenic Therapeutics, Inc.
- Nasdaq Capital Market (company) — Exchange where Protagenic Therapeutics was listed
- November 19, 2024 (date) — Date of the earliest event reported
- November 22, 2024 (date) — Filing date of the 8-K report
FAQ
What specific listing rule or standard has Protagenic Therapeutics failed to satisfy?
The provided excerpt of the 8-K filing does not specify the exact listing rule or standard that Protagenic Therapeutics has failed to satisfy.
What is the current status of Protagenic Therapeutics' listing on the Nasdaq Capital Market?
The filing is a 'Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard,' indicating that the company is facing issues with its current listing on the Nasdaq Capital Market.
Has Protagenic Therapeutics announced a transfer of listing to another exchange?
The filing mentions 'Transfer of Listing' as an item information, suggesting this is a possibility or part of the event being reported, but specific details of a new listing are not provided in this excerpt.
What is the ticker symbol for Protagenic Therapeutics?
The ticker symbol for Protagenic Therapeutics, Inc. is PTIX.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on November 19, 2024.
Filing Stats: 580 words · 2 min read · ~2 pages · Grade level 12.6 · Accepted 2024-11-22 16:12:37
Key Financial Figures
- $2,500,000 — that we did not comply with the minimum $2,500,000 stockholders' equity requirement for co
Filing Documents
- form8-k.htm (8-K) — 44KB
- 0001493152-24-047376.txt ( ) — 272KB
- ptix-20241119.xsd (EX-101.SCH) — 4KB
- ptix-20241119_def.xml (EX-101.DEF) — 31KB
- ptix-20241119_lab.xml (EX-101.LAB) — 37KB
- ptix-20241119_pre.xml (EX-101.PRE) — 28KB
- form8-k_htm.xml (XML) — 6KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PROTAGENIC THERAPEUTICS, INC. Date: November 22, 2024 By: /s/ Alexander K. Arrow Name: Alexander K. Arrow Title: Chief Financial Officer 3